Every FDA Commissioner inherits unfinished business. Scientific advances continue whether regulators are ready for them or not, and every new Commissioner must decide whether the Agency will merely keep pace or help shape the future of medicine.
Kyle Diamantas' first public statement as Acting FDA Commissioner suggests he understands that challenge.
His policy statement, An Enduring Mission in a New Era: The FDA Public Health Pillars, does more than outline administrative priorities. It recognizes that FDA's responsibilities now extend well beyond reviewing individual drug applications. The Agency still exists to ensure that medicines are safe, effective, and manufactured to the highest quality standards. But those responsibilities now sit within a much larger ecosystem that includes advanced manufacturing, artificial intelligence, resilient supply chains, and America's global leadership in biomedical innovation.
That is a significant shift in emphasis, and a welcome one.
Perhaps the most striking passage in Diamantas' statement concerns patients with serious and rare diseases. "Every moment matters as they await new treatment options," he writes. That simple observation captures something regulators, clinicians, and patients have increasingly come to recognize. For many progressive diseases, time is not an abstraction. It is biology. Muscle function lost in ALS is rarely recovered. Neurons destroyed by Huntington's disease do not regenerate. Every month spent waiting for a better therapy has consequences that cannot be reversed.
Recognizing that reality does not mean lowering FDA's standards. It means acknowledging that regulatory science must continue to evolve alongside medical science.
That evolution is already underway. Cell therapies, gene editing, RNA medicines, and increasingly precise biomarker-driven treatments do not fit neatly into the regulatory framework developed for blockbuster drugs serving millions of patients. FDA has responded by incorporating new scientific tools into its decision-making, including biomarkers, real-world evidence, patient experience, and more sophisticated manufacturing science. Randomized clinical trials remain the foundation of regulatory review, but they are no longer the only source of scientifically meaningful information.
Diamantas' emphasis on artificial intelligence deserves similar attention, although perhaps for a different reason than many headlines suggest. Too much of the public discussion treats AI as though it will somehow replace regulatory scientists. That misunderstands both the technology and the job. FDA reviewers are not simply processing information; they are exercising scientific judgment. Artificial intelligence can analyze manufacturing trends that would otherwise remain hidden, identify subtle safety signals across enormous datasets, and help reviewers make better use of real-world evidence. What it cannot do is decide whether a medicine's benefits outweigh its risks. That responsibility—and the accountability that accompanies it—will remain human.
The more interesting question is how AI changes the quality of those human decisions.
Used thoughtfully, these technologies allow regulators to spend less time searching for information and more time evaluating it. They improve the quality of scientific judgment rather than replacing it. That distinction is likely to define the next decade of regulatory modernization.
Diamantas also places unusual emphasis on pharmaceutical manufacturing and supply-chain resilience. That may prove to be one of the most consequential parts of his statement. For years, Washington has treated drug shortages as isolated events. A manufacturing line fails. A supplier cannot deliver. Production is interrupted. Government responds. Then attention shifts elsewhere until the next shortage occurs.
The pattern has become familiar because we continue to mistake symptoms for causes.
Drug shortages rarely begin with the event that makes the evening news. They begin years earlier, when supply chains become too concentrated, redundancy disappears, quality systems stagnate, or manufacturers face incentives that reward efficiency while undervaluing resilience. By the time a hospital begins rationing essential medicines, the underlying weaknesses have already been in place for years.
That is why Diamantas' discussion of domestic manufacturing, cybersecurity, preparedness, and resilient supply chains deserves careful attention. These are no longer separate policy conversations. Together they describe the architecture of a pharmaceutical enterprise capable of withstanding disruption without sacrificing patient access or scientific integrity.
Peter J. Pitts is President of the Center for Medicine in the Public Interest and a former FDA Associate Commissioner. Cathy McMorris Rodgers represented Washington's 5th Congressional District in the U.S. House of Representatives from 2005 to 2025 and served as Chair of the House Energy and Commerce Committee, where she helped shape legislation affecting healthcare, biomedical innovation, and FDA oversight. Both Pitts and McMorris Rodgers are senior fellows at the US-Israel Education Association.
